Xeris Biopharma Holdings Inc. (XERS)
NASDAQ: XERSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
XERS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $3.10B
- Forward P/E
- 63.64
- EPS (TTM)
- -$0.03
- Dividend yield
- None
- 52-week range
- 5.25 – 17.28
- Day range
- 16.53 – 17.04
- Volume / Avg
- 2.86M / 2.86M
- Beta
- —
- Shares outstanding
- 182.70M
52-week range
XERS stock today
On Nov 20, XERS ended the session at $16.97, adding $0.35 (2.11%), versus the S&P 500's 3.70% decline. At this level, XERS sits near the top of its 52-week range of $5.25 to $17.28: 1.8% below the high, set on Nov 18, 2026 and 223.2% above the low. XERS is up 116.2% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 148.5%.
Xeris Biopharma has posted a net loss over the last twelve months (EPS of -$0.03), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Xeris Biopharma
Company profileXeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. John P. Shannon
- Headquarters
- Chicago, IL
- Employees
- 435
- IPO year
- 2018
- Website
- xerispharma.com
Financial highlights
Full financialsIn fiscal 2025, Xeris Biopharma generated $291.8 million in revenue, up 43.7% from fiscal 2024, its 5th consecutive year of revenue growth. Net income was $554,000, for a net margin of 0.2% versus a median of -85.9% in the prior 5 years. Gross margin was 85.4% (up from 81.9%) and operating margin 8.5%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $291.85M | $203.07M | $163.91M | $110.25M | $49.59M |
| Growth | +43.72% | +23.89% | +48.68% | +122.32% | +142.67% |
| Net income | $554.00K | $-54.84M | $-62.26M | $-94.66M | $-122.72M |
| EPS (diluted) | $0.00 | $-0.37 | $-0.45 | $-0.70 | $-1.55 |
Analyst forecast
ForecastConsensus (7 analysts)
strong_buy
Avg. price target
$17.29+1.89%
- Strong buy 1
- Buy 5
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $0.06 vs $0.02
- Surprise
- +200.00%
XERS news
All XERS news- XERS Crosses Above Average Analyst TargetNasdaqXERS, HEI.A
- Xeris Biopharma Holdings, Inc. Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue Guidance to $395 Million to $405 MillionNasdaqXERS, WSO.B
- Xeris Biopharma Reports Third Quarter 2026 Financial Results and Business HighlightsBusiness Wire
- Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026Business Wire
Xeris Biopharma peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BHCBausch Health Companies Inc. | 8.22 | -3.97% | $3.08B | vs XERS |
| VKTXViking Therapeutics Inc. | 24.77 | -4.14% | $3.16B | vs XERS |
| ABCLAbCellera Biologics Inc. | 9.69 | -7.45% | $3.16B | vs XERS |
| LEGNLegend Biotech Corporation ADR | 15.25 | -5.28% | $2.96B | vs XERS |
| ACADACADIA Pharmaceuticals Inc. | 17.11 | -2.73% | $2.96B | vs XERS |
| DYNDyne Therapeutics Inc. | 15.50 | -3.31% | $2.90B | vs XERS |
| ARQTArcutis Biotherapeutics Inc. | 26.36 | -2.98% | $3.33B | vs XERS |
| AMLXAmylyx Pharmaceuticals Inc. | 26.02 | -0.69% | $3.35B | vs XERS |
Indexes, lists and sector
Xeris Biopharma stock FAQ
What is Xeris Biopharma's stock price today?
XERS last traded at $16.97 as of Nov 20, 4:00 PM EST, up 2.11% on the day. Prices are delayed at least 15 minutes.
Who is Xeris Biopharma's CEO?
Mr. John P. Shannon is the chief executive officer of Xeris Biopharma Holdings Inc., which has about 435 employees.
What is the XERS 52-week high?
The 52-week high for XERS is $17.28 and the 52-week low is $5.25. The stock is currently 1.8% below its high.